TME Clinical Trials in Tianjin, Tianjin Municipality
18 recruitingTianjin, Tianjin Municipality, China
Showing 1–18 of 18 trials
Recruiting
Phase 1Phase 2
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
TreatmentAMLIDH1 Mutation
Institute of Hematology & Blood Diseases Hospital, China23 enrolled1 locationNCT06611839
Recruiting
Phase 2
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07234019
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07297563
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07362199
Recruiting
Phase 2
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06168851
Recruiting
Phase 2
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT06838962
Recruiting
Phase 1Phase 2
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06776510
Recruiting
Phase 2
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07063199
Recruiting
Phase 2
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
Lung CancersRadiation Treatment for Tumors
Tianjin Medical University Cancer Institute and Hospital84 enrolled1 locationNCT06775678
Recruiting
Phase 2
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Elderly (People Aged 65 or More)Sever Aplastic AnaemiaImmunosuppressive Treatment
Institute of Hematology & Blood Diseases Hospital, China65 enrolled1 locationNCT07010237
Recruiting
Phase 2
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06799611
Recruiting
Phase 2
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
TreatmentThrombocytopeniaAntiphospholipid Syndrome
Institute of Hematology & Blood Diseases Hospital, China10 enrolled2 locationsNCT05199909
Recruiting
Phase 2
Anti-CD38 Antibody Treating Evans Syndrome
TreatmentEvan Syndrome
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT06014775
Recruiting
Phase 2
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT05214391
Recruiting
Not Applicable
TACS on High-inflammatory and Refractory Depression
InflammationTreatment Resistant Depression (TRD)
Tianjin Anding Hospital52 enrolled1 locationNCT06812923
Recruiting
Not Applicable
Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography
ThrombectomyStroke, AcuteMedical Treatment+1 more
Tianjin Huanhu Hospital350 enrolled1 locationNCT06654375
Recruiting
Ischemic Post-conditioning in the Treatment of Acute Ischemic Stroke
Acute Ischemic StrokeLarge Vessel OcclusionIntracranial Artery Occlusion With Cerebral Infarction+1 more
Ming Wei200 enrolled1 locationNCT06456437
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891